GLENMARK

Glenmark Pharmaceuticals Limited · NSE · INE935A01035 · F&O · lot 375 · 272 sessions on record

₹2,331.00▼ −3.70 · −0.2%from ₹2,334.70 the session before · 1 Oct 2026 close · NSE end of day

Open: ₹2,339.00
High: ₹2,360.00
Low: ₹2,279.30
Day's range: ₹813.5% of the previous close
VWAP: ₹2,324.84close +0.27% from it
Volume, shares: 9.7 L1.76× the 20-session average
Turnover, ₹ crore: 230
Trades: 56,00017 shares per trade
Previous close: ₹2,334.70−3.70 to the close
Price band, next session: ₹2,097.90 – ₹2,564.1010% either side of the close · dynamic, widened in 5% steps when hit

Day range64% of the way up

₹2,279.30₹2,360.00

52-week range72% of the way up

₹1,792.60 28 Oct₹2,537.60 28 Aug

−8.1% from the high · +30% from the low

The desk read · 1 Octexpiry 27 Oct · 26 days

long unwinding

futures read

price −0.2% · OI −0.8%

+6.10

futures premium, ₹

+0.3% to spot ₹2,331.00

0.64

puts per call, by OI

by volume 0.80

2,360

max pain

+1.2% from the close

▼ −0.8%

futures OI on the day

−240 lots · 29,000 open

Long unwinding into a 26-day expiry: futures OI −0.8% on a −0.2% day, the most call OI sits at 2,400, the most put OI at 2,300, max pain 2,360.

Futures and options

1 Oct close · lot 375 · NSE end of day

GLENMARK futures closed at ₹2,337.10, +0.3% to spot, with 100% of open interest in the 27 Oct contract, and the 2,340 straddle prices a move of about ±5.6% by expiry.

Futures by expiryall 3 contracts NSE lists on the stock · basis against the spot close ₹2,331.00

Futures by expiry, basis against the spot close ₹2,331.00
Expiry	Close ₹	Basis ₹ · %	Annualised %	OI lots · on the day	Share of OI %	Contracts traded
27 Oct26 days	₹2,337.10	+6.10+0.3%	+3.7%	28,000▼ −0.9% · −250 lots	100	2,900
23 Nov53 days	₹2,344.60	+13.60+0.6%	+4.0%	89▲ +11.3% · +9.0 lots	0.31	51
29 Dec89 days	₹2,415.20	+84.20+3.6%	+15%	1.00.0% · 0.00 lots	0.00	0.00

0.32% of futures OI sits beyond the 27 Oct contract · 43 of 73 listed contracts traded · 6,600 option contracts changed hands

Options27 Oct expiry · 26 days

The 2,340 straddle closed at ₹130.40 (call 63.10 + put 67.30), pricing a move of about ±5.6% by the 27 Oct expiry. In the last 253 windows of 19 sessions, GLENMARK moved more than that 104 times.

Call OI, lots: 3,00011 L shares
Put OI, lots: 1,9007.2 L shares
Puts per call, by OI: 0.64by volume 0.80
Max pain: 2,360+1.2% from the close
Contracts traded: 43 of 73listed for this expiry

Open interest by strike, lotstop three strikes each side

Calls

Strike

Puts

460

2,500

580

2,400

200

440

2,300

240

2,200

210

Open interest added on the day, lotsthree largest additions each side

Calls

Strike

Puts

+47

2,500

+46

2,420

+130

2,400

2,280

+40

2,200

+120

2,100

+120

Close ₹ · Nifty 50 rebased to the first close · futures open interest by the day's build-up126 sessions to 1 Oct · axis fixed at 4 × ATR-14 around the last close · hover or tap a session and the read beside the chart follows it

272 sessions on file · from 28 Aug

GLENMARK close
Nifty 50, rebased
long build-up · price up, OI up
short build-up · price down, OI up
short covering · price up, OI down
long unwinding · price down, OI down

Session read · latest close: 1 Oct 2026
Close ₹ · day %: ₹2,331.00▼ −0.2% on the previous close
Against Nifty 50: Nifty −0.9%+0.7 pp difference on the day
Futures OI, lots: 29,000−240 lots · −0.8% on the day
The day's build-up: long unwindingprice −0.2% · OI −0.8%
Against the averages: below 20 · below 5020-session ₹2,418.33 (−3.6%) · 50-session ₹2,353.89 (−0.97%)
Volume: 1.76×the previous 20 sessions · 9.7 L shares
Extremes on the day: futures OI at a 60-session low

The market after the news

close against the last close before each bulletin · Nifty 50 over the same sessions

After the last 8 bulletins, GLENMARK closed higher five sessions later in 3 of 8.

Close after each bulletin on the day, one session later and five sessions later, with Nifty 50 and futures open interest
Bulletin	Day of the news	1 session later	5 sessions later	Futures OI on the day
27 MarIndian stocks rise despite rupee plunge and FII sell-off	▲ +0.1%Nifty −2.1% · +2.2 pp	▼ −1.7%Nifty −4.2% · +2.5 pp	▼ −2.5%Nifty −0.8% · −1.7 pp	▼ −1.2%short covering
4 FebGlenmark Pharma aims for zero debt by March 2026	▲ +0.3%Nifty +0.2% · +0.1 pp	▲ +0.8%Nifty −0.3% · +1.1 pp	▲ +3.1%Nifty +0.9% · +2.2 pp	▼ −0.6%short covering
3 FebGlenmark Pharma targets zero gross debt by March 2026	▲ +0.3%Nifty +0.2% · +0.1 pp	▲ +0.8%Nifty −0.3% · +1.1 pp	▲ +3.1%Nifty +0.9% · +2.2 pp	▼ −0.6%short covering
1 FebGlenmark Pharma faces GST search amid Q3 results	▼ −1.0%Nifty +1.1% · −2.1 pp	▲ +0.7%Nifty +3.6% · −2.9 pp	▲ +1.8%Nifty +4.2% · −2.4 pp	▲ +2.8%short build-up
1 FebGlenmark Pharma faces GST search amid Q3 results	▼ −3.8%Nifty −2.0% · −1.8 pp	▼ −4.7%Nifty −0.9% · −3.8 pp	▼ −4.0%Nifty +1.5% · −5.5 pp	▼ −0.2%long unwinding
31 JanGlenmark Pharma Q3 profit rises 16%, SAIL exceeds estimates	▼ −3.8%Nifty −2.0% · −1.8 pp	▼ −4.7%Nifty −0.9% · −3.8 pp	▼ −4.0%Nifty +1.5% · −5.5 pp	▼ −0.2%long unwinding
31 JanGlenmark Pharma Q3 profit rises 16%, SAIL exceeds estimates	▼ −3.8%Nifty −2.0% · −1.8 pp	▼ −4.7%Nifty −0.9% · −3.8 pp	▼ −4.0%Nifty +1.5% · −5.5 pp	▼ −0.2%long unwinding
15 NovGlenmark Pharma Q2 profit rises 72%, revenue up 76%	▼ −1.4%Nifty +0.4% · −1.8 pp	▼ −2.8%Nifty 0.0% · −2.8 pp	▼ −2.8%Nifty +0.2% · −3.0 pp	▲ +27.7%short build-up

8 of 9 bulletins

Quarterly results

consolidated · latest filed 31 Jul, 07:53 pm IST · NSE filings

Revenue ₹4,018 cr, +23% on a year earlier; profit ₹483 cr, +930% in the Jun 2026 quarter, consolidated.

Last 8 quarters, consolidated₹ crore as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, Nifty 50 over the same session

Quarterly results of GLENMARK on the consolidated basis with the market's move on the first session after each filing
Quarter	Revenue ₹ cr	Revenue YoY	Profit ₹ cr	Profit YoY	EPS ₹	Market on the day
Jun 2026filed 31 Jul	₹4,018 cr	▲ +23%	₹483 cr	▲ +930%	17.11	▼ −0.2%Nifty +1.6% · −1.8 pp
Mar 2026filed 29 May · audited	₹3,771 cr	▲ +16%	₹301 cr	▲ +6,800%	10.68	▼ −3.2%Nifty −0.7% · −2.5 pp
Dec 2025filed 30 Jan	₹3,901 cr	▲ +15%	₹403 cr	▲ +16%	14.28	▼ −3.8%Nifty −2.0% · −1.8 pp
Sept 2025filed 14 Nov	₹6,047 cr	▲ +76%	₹610 cr	▲ +72%	21.62	▼ −1.4%Nifty +0.4% · −1.8 pp
Jun 2025filed 14 Aug	₹3,264 cr	▲ +0.62%	₹47 cr	▼ −86%	1.66	▼ −3.5%Nifty +1.0% · −4.5 pp
Mar 2025filed 23 May · audited	₹3,256 cr	▲ +6.3%	₹4 cr	—	0.16	▼ −2.1%Nifty +0.6% · −2.7 pp
Dec 2024filed 14 Feb	₹3,388 cr	▲ +35%	₹348 cr	—	12.33	▲ +3.8%Nifty +0.1% · +3.7 pp
Sept 2024filed 15 Nov	₹3,434 cr	▲ +7.1%	₹354 cr	—	12.55	▼ −3.1%Nifty −0.3% · −2.8 pp

By financial yearApril to March · each year the sum of its four quarters as filed, consolidated · EPS summed across the quarters · only complete years

Financial-year results of GLENMARK on the consolidated basis, summed from the quarters filed
Year	Revenue ₹ cr	Revenue YoY	Profit ₹ cr	Profit YoY	EPS ₹
FY26to Mar 2026	₹16,983 cr	▲ +27%	₹1,362 cr	▲ +30%	48.24
FY25to Mar 2025	₹13,322 cr	▲ +9.4%	₹1,047 cr	—	37.10
FY24to Mar 2024	₹12,179 cr	—	−₹1,436 cr	—	-53.22

Fundamentals

consolidated · filings to Jun 2026 · close ₹2,331.00 on 1 Oct

GLENMARK trades at 37 times trailing earnings against 38 for its industry, 6.3 times book value, revenue +33% over twelve months, a 0.43% dividend yield, market cap ₹66,000 cr.

Valuationarithmetic on filings and the close · each cell names what it rests on · — where an input is missing

Market cap: ₹66,000 cron 1 Oct · free float ₹35,000 cr
Price to earnings: 37consolidated · four quarters to Jun 2026 · industry 38
Trailing EPS: ₹63.69diluted · consolidated · four quarters to Jun 2026
Price to book: 6.3consolidated · balance sheet to Mar 2026
Book value a share: ₹372.46consolidated · balance sheet to Mar 2026 · over NSE's share count
Debt to equity: 0.00borrowings over equity · consolidated · balance sheet to Mar 2026
Return on equity: 19%trailing profit over average equity · consolidated
Dividend yield: 0.43%₹10.00 a share in 365 days
Face value: ₹1a share
Shares outstanding: 28 cron 1 Oct

Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated

Revenue, trailing 12 months: ₹17,737 crfour quarters to Jun 2026
Revenue growth, 12 months: ▲ +33%against the twelve months before
Revenue 3-year CAGR: ▲ +9.2%trailing twelve months against the twelve months 3 years earlier · consolidated
Profit, trailing 12 months: ₹1,798 crfour quarters to Jun 2026
Profit growth, 12 months: ▲ +140%against the twelve months before
Profit 3-year CAGR: ▲ +74%trailing twelve months against the twelve months 3 years earlier · consolidated

PeersBSE sub-group Pharmaceuticals · F&O stocks with filings on record · industry P/E 38, market caps over trailing profit of 13 stocks

Stocks in the BSE sub-group Pharmaceuticals with market cap, price to earnings and price to book
Stock	Market cap ₹	P/E	P/B	Close ₹
SUNPHARMASun Pharmaceutical Industries Limited	4,30,000 cron 1 Oct	36consolidated	5.2	₹1,801.00
DIVISLABDivi's Laboratories Limited	2,50,000 cron 1 Oct	52consolidated	15	₹9,249.00
TORNTPHARMTorrent Pharmaceuticals Limited	1,80,000 cron 1 Oct	76consolidated	10	₹4,767.30
ZYDUSLIFEZydus Lifesciences Limited	1,10,000 cron 1 Oct	26consolidated	3.9	₹1,145.70
CIPLACipla Limited	1,10,000 cron 1 Oct	32consolidated	3.1	₹1,344.00
LAURUSLABSLaurus Labs Limited	1,10,000 cron 1 Oct	85consolidated	20	₹1,984.00
MANKINDMankind Pharma Limited	1,00,000 cron 1 Oct	51consolidated	6.3	₹2,535.00
DRREDDYDr. Reddy's Laboratories Limited	1,00,000 cron 1 Oct	31consolidated	2.6	₹1,206.20
AUROPHARMAAurobindo Pharma Limited	96,000 cron 1 Oct	26consolidated	2.5	₹1,676.80
LUPINLupin Limited	93,000 cron 1 Oct	17consolidated	4.1	₹2,031.20
GLENMARKGlenmark Pharmaceuticals Limited	66,000 cron 1 Oct	37consolidated	6.3	₹2,331.00
ALKEMAlkem Laboratories Limited	62,000 cron 1 Oct	29consolidated	4.3	₹5,220.00
BIOCONBiocon Limited	60,000 cron 1 Oct	110consolidated	1.6	₹370.70
ABBOTINDIAAbbott India Limited	57,000 cron 1 Oct	—	—	₹26,840.00
IPCALABIPCA Laboratories Limited	49,000 cron 1 Oct	—	5.2	₹1,943.20
GLANDGland Pharma Limited	47,000 cron 1 Oct	—	4.6	₹2,874.40
GLAXOGlaxoSmithKline Pharmaceuticals Limited	47,000 cron 1 Oct	—	21	₹2,771.10
AJANTPHARMAjanta Pharma Limited	45,000 cron 1 Oct	—	9.9	₹3,581.00
EMCUREEmcure Pharmaceuticals Limited	37,000 cron 1 Oct	—	7.4	₹1,944.60
WOCKPHARMAWockhardt Limited	34,000 cron 1 Oct	—	6.4	₹2,083.90
SAILIFESai Life Sciences Limited	33,000 cron 1 Oct	—	13	₹1,541.20
NEULANDLABNeuland Laboratories Limited	28,000 cron 1 Oct	—	15	₹21,505.00
RUBICONRubicon Research Limited	27,000 cron 1 Oct	—	21	₹1,630.90
PPLPHARMAPiramal Pharma Limited	26,000 cron 1 Oct	—	3.2	₹197.95
ACUTAASAcutaas Chemicals Limited	26,000 cron 1 Oct	—	15	₹3,196.50
SHILPAMEDShilpa Medicare Limited	21,000 cron 1 Oct	—	8.0	₹1,064.10
GRANULESGranules India Limited	20,000 cron 1 Oct	—	4.0	₹821.75
CAPLIPOINTCaplin Point Laboratories Limited	20,000 cron 1 Oct	—	5.5	₹2,631.90
PFIZERPfizer Limited	18,000 cron 1 Oct	—	4.2	₹3,858.90
ONESOURCEOnesource Specialty Pharma Limited	17,000 cron 1 Oct	—	3.0	₹1,508.00
COHANCECohance Lifesciences Limited	17,000 cron 1 Oct	—	4.3	₹451.30
ALIVUSAlivus Life Sciences Limited	17,000 cron 1 Oct	—	5.1	₹1,374.20
ERISEris Lifesciences Limited	16,000 cron 1 Oct	—	4.2	₹1,189.80
NATCOPHARMNatco Pharma Limited	16,000 cron 1 Oct	—	1.8	₹821.30
APLLTDAlembic Pharmaceuticals Limited	16,000 cron 1 Oct	—	2.8	₹815.25
JUBLPHARMAJubilant Pharmova Limited	16,000 cron 1 Oct	—	2.2	₹999.30
ASTRAZENAstraZeneca Pharma India Limited	15,000 cron 1 Oct	—	17	₹6,031.00
MARKSANSMarksans Pharma Limited	15,000 cron 1 Oct	—	4.8	₹325.60
CONCORDBIOConcord Biotech Limited	14,000 cron 1 Oct	—	7.1	₹1,374.10
AKUMSAkums Drugs and Pharmaceuticals Limited	13,000 cron 1 Oct	—	3.8	₹813.10
CORONACORONA Remedies Limited	12,000 cron 1 Oct	—	17	₹2,029.40
BLUEJETBlue Jet Healthcare Limited	10,000 cron 1 Oct	—	7.5	₹541.80
VIYASHViyash Scientific Limited	10,000 cron 1 Oct	—	3.3	₹231.75
STARStrides Pharma Science Limited	10,000 cron 1 Oct	—	3.2	₹1,084.80
PGHLProcter & Gamble Health Limited	8,900 cron 1 Oct	—	17	₹5,360.00
AARTIPHARMAarti Pharmalabs Limited	8,800 cron 1 Oct	—	4.1	₹968.50
SANOFICONRSanofi Consumer Healthcare India Limited	8,700 cron 1 Oct	—	25	₹3,787.20
SYMBIOTECSymbiotec Pharmalab Limited	7,700 cron 1 Oct	—	—	₹1,198.00
SUPRIYASupriya Lifescience Limited	7,500 cron 1 Oct	—	6.3	₹931.00
MOREPENLABMorepen Laboratories Limited	7,300 cron 1 Oct	—	5.9	₹133.70
SANOFISanofi India Limited	7,000 cron 1 Oct	—	8.5	₹3,037.40
INNOVACAPInnova Captab Limited	6,700 cron 1 Oct	—	6.1	₹1,168.00
SPARCSun Pharma Advanced Research Company Limited	6,300 cron 1 Oct	—	4.7	₹194.15
SENORESSenores Pharmaceuticals Limited	6,200 cron 1 Oct	—	6.4	₹1,349.60
IOLCPIOL Chemicals and Pharmaceuticals Limited	6,100 cron 1 Oct	—	3.4	₹209.40
ORCHPHARMAOrchid Pharma Limited	5,900 cron 1 Oct	—	4.6	₹990.00
FDCFDC Limited	5,500 cron 1 Oct	—	2.2	₹335.90
GUJTHEMGujarat Themis Biosyn Limited	5,000 cron 1 Oct	—	—	₹381.80
NOVARTINDNovartis India Limited	4,900 cron 1 Oct	—	—	₹1,965.00
RPGLIFERPG Life Sciences Limited	4,800 cron 1 Oct	—	8.0	₹2,930.70
SMSPHARMASMS Pharmaceuticals Limited	4,400 cron 1 Oct	—	5.6	₹471.30
GUFICBIOGufic Biosciences Limited	4,200 cron 1 Oct	—	6.3	₹418.40
AARTIDRUGSAarti Drugs Limited	3,800 cron 1 Oct	—	2.5	₹421.00
UNICHEMLABUnichem Laboratories Limited	3,800 cron 1 Oct	—	1.4	₹535.05
KPLKwality Pharmaceuticals Limited	3,700 cron 1 Oct	—	—	₹3,564.40
SOLARASolara Active Pharma Sciences Limited	3,400 cron 1 Oct	—	2.7	₹714.85
INDSWFTLABInd-Swift Laboratories Limited	3,400 cron 1 Oct	—	2.5	₹395.15
SHUKRAPHARShukra Pharmaceuticals Limited	2,700 cron 1 Oct	—	—	₹61.80
HIKALHikal Limited	2,700 cron 1 Oct	—	2.2	₹218.15
VENUSREMVenus Remedies Limited	2,400 cron 1 Oct	—	3.6	₹1,796.70
DCALDishman Carbogen Amcis Limited	2,400 cron 1 Oct	—	0.35	₹150.35
INDOCOIndoco Remedies Limited	2,300 cron 1 Oct	—	2.5	₹251.75
SAIPARENTSai Parenterals Limited	2,300 cron 1 Oct	—	4.7	₹523.65
SYNCOMFSyncom Formulations (India) Limited	2,300 cron 1 Oct	—	5.4	₹23.95
FREDUNFredun Pharmaceuticals Limited	2,200 cron 1 Oct	—	—	₹1,355.20
WINDLASWindlas Biotech Limited	2,200 cron 1 Oct	—	—	₹1,082.40
PANACEABIOPanacea Biotec Limited	2,200 cron 1 Oct	—	2.6	₹359.05
HESTERBIOHester Biosciences Limited	1,800 cron 1 Oct	—	4.9	₹2,126.80
NGLFINENGL Fine-Chem Limited	1,800 cron 1 Oct	—	5.5	₹2,924.00
AHCLAnlon Healthcare Limited	1,700 cron 1 Oct	—	6.8	₹32.85
FERMENTAFermenta Biotech Limited	1,600 cron 1 Oct	—	—	₹553.25
JAGSNPHARMJagsonpal Pharmaceuticals Limited	1,500 cron 1 Oct	—	5.5	₹231.75
AMRUTANJANAmrutanjan Health Care Limited	1,500 cron 1 Oct	—	4.0	₹513.20
KOPRANKopran Limited	1,400 cron 1 Oct	—	2.6	₹282.05
BPLPHARMABharat Parenterals Limited	1,200 cron 1 Oct	—	—	₹1,720.40
LINCOLNLincoln Pharmaceuticals Limited	1,200 cron 1 Oct	—	1.5	₹582.05
BAJAJHCAREBajaj Healthcare Limited	1,100 cron 1 Oct	—	2.0	₹322.95
SIGACHISigachi Industries Limited	1,100 cron 1 Oct	—	2.0	₹28.35
THEMISMEDThemis Medicare Limited	1,000 cron 1 Oct	—	2.6	₹113.20
SGRLShree Ganesh Remedies Limited	890 cron 1 Oct	—	—	₹694.25
ANUHPHRAnuh Pharma Limited	860 cron 1 Oct	—	2.4	₹85.85
ZIMLABZim Laboratories Limited	740 cron 1 Oct	—	2.5	₹137.00
WANBURYWanbury Limited	690 cron 1 Oct	—	4.8	₹198.00
ALBERTDAVDAlbert David Limited	490 cron 1 Oct	—	1.3	₹856.70
MEDICAMEQMedicamen Biotech Limited	470 cron 17 Sept	—	1.7	₹346.30
HALEOSLABSHALEOS LABS LIMITED	450 cron 1 Oct	—	2.0	₹1,490.00
JENBURPHJenburkt Pharmaceuticals Limited	400 cron 1 Oct	—	—	₹915.25
AAREYDRUGSAarey Drugs & Pharmaceuticals Limited	290 cron 1 Oct	—	2.0	₹103.85
NECLIFENectar Lifesciences Limited	200 cron 1 Oct	—	0.34	₹10.25
MEDICOMedico Remedies Limited	180 cron 1 Oct	—	2.4	₹21.85
BALPHARMABal Pharma Limited	170 cron 1 Oct	—	2.0	₹105.75
BROOKSBrooks Laboratories Limited	160 cron 1 Oct	—	1.3	₹54.80
KREBSBIOKrebs Biochemicals and Industries Limited	150 cron 1 Oct	—	—	₹68.05
PARNAXLABParnax Lab Limited	130 cron 1 Oct	—	—	₹113.15
ALPAAlpa Laboratories Limited	120 cron 1 Oct	—	0.67	₹59.25
MAKERSLMakers Laboratories Limited	110 cron 1 Oct	—	—	₹183.50
SUNLOCSunil Healthcare Limited	72 cron 1 Oct	—	—	₹70.10
VINEETLABVineet Laboratories Limited	69 cron 1 Oct	—	1.5	₹35.90
BIOFILCHEMBiofil Chemicals & Pharmaceuticals Limited	48 cron 1 Oct	—	2.2	₹29.30
MANGALAMMangalam Drugs And Organics Limited	46 cron 1 Oct	—	0.45	₹29.15
MEDICAPQMedi Caps Limited	31 cron 17 Sept	—	—	₹24.80
ORTINGLOBEORTIN GLOBAL LIMITED	12 cron 1 Oct	—	9.5	₹14.50
AMANTAAmanta Healthcare Limited	—	—	—	—
AMBALALSAAmbalal Sarabhai Enterprises Limited	—	—	—	—
BAFNAPHBafna Pharmaceuticals Limited	—	—	—	—
BLISSGVSBliss GVS Pharma Limited	—	—	—	—
KILITCHKilitch Drugs (India) Limited	—	—	—	—
LASALasa Supergenerics Limited	—	—	—	—
LYKALABSLyka Labs Limited	—	—	—	—
NATCAPSUQNatural Capsules Limited	—	—	—	—
VALIANTLABValiant Laboratories Limited	—	—	—	—
VIVIMEDLABVivimed Labs Limited	—	—	—	—

Shareholding

quarter to 30 Jun · none pledged · NSE filings

Promoters hold 46.6%, foreign portfolio investors 20.9%, mutual funds 16.8% and insurance companies 1.0%, as filed for the quarter to 30 Jun.

46.6%20.9%16.8%11.4%

By category, last 5 quarterspercent of shares · beneath each figure, the change in percentage points against the previous quarter on file

Shareholding of GLENMARK by category over the last 5 quarters with the change against the previous quarter
Category	30 Jun	31 Mar	31 Dec	30 Sept	30 Jun
Promoters	46.650.00 pp	46.650.00 pp	46.650.00 pp	46.650.00 pp	46.65
Foreign portfolio investors	20.89▲ +0.54 pp	20.35▲ +1.15 pp	19.20▼ −1.53 pp	20.73▲ +0.11 pp	20.62
Mutual funds	16.76▼ −0.04 pp	16.80▼ −1.06 pp	17.86▲ +1.55 pp	16.31▲ +0.76 pp	15.55
Insurance companies	1.02▲ +0.02 pp	1.00▼ −0.03 pp	1.03▲ +0.37 pp	0.66▲ +0.20 pp	0.46
Banks and financial institutions	0.82▼ −0.66 pp	1.48▲ +0.28 pp	1.20▼ −0.44 pp	1.64▲ +0.01 pp	1.63
Individual investors	11.42▲ +0.27 pp	11.15▼ −0.40 pp	11.55▼ −0.04 pp	11.59▼ −0.86 pp	12.45
Bodies corporate	2.08▼ −0.04 pp	2.12▼ −0.04 pp	2.16▲ +0.09 pp	2.07▼ −0.22 pp	2.29
Government	0.040.00 pp	0.040.00 pp	0.040.00 pp	0.040.00 pp	0.04
Others	0.32▼ −0.11 pp	0.43▲ +0.12 pp	0.310.00 pp	0.310.00 pp	0.31

Corporate actions

NSE and BSE records

Nothing upcoming on record; the last was a dividend of ₹2.50 a share, ex-date 31 Aug 2026.

Actionsex-dates · upcoming first, then the last eight · dividends in rupees a share, bonus and split as ratios

Corporate actions of GLENMARK, upcoming first, then the most recent
Ex-date	Action	Amount or ratio	Record date	Source
recent
31 Aug 2026	dividend	₹2.50	31 Aug 2026	BSE
3 Oct 2025	dividend	₹2.50	3 Oct 2025	BSE
15 Sept 2025	dividend	₹2.50	15 Sept 2025	BSE
13 Sept 2024	dividend	₹2.50	—	BSE

Calendaras notified to the exchange

Next results: —no board meeting notified yet
Dividends in 365 days: ₹10.00a share · ex-dates inside the year
Last dividend: ₹2.50ex-date 31 Aug 2026

Price history

272 sessions on record · to 1 Oct · NSE end of day

GLENMARK is −5.2% over 20 sessions against Nifty's −6.2%, 8.1% below its 52-week high, realised volatility 30% annualised.

Returns against Nifty 50longest window first · Nifty 50 over the same sessions

Returns of the stock and Nifty 50 over six windows, longest first
Window	From ₹	GLENMARK %	Nifty 50 %	Difference pp
250 sessionssince 26 Sept	₹1,971.75	▲ +18%	▼ −9.1%	+27
120 sessionssince 9 Apr	₹2,169.18	▲ +7.5%	▼ −5.7%	+13
60 sessionssince 8 Jul	₹2,223.60	▲ +4.8%	▼ −6.1%	+11
20 sessionssince 2 Sept	₹2,459.90	▼ −5.2%	▼ −6.2%	+1.0
5 sessionssince 24 Sept	₹2,430.40	▼ −4.1%	▼ −2.8%	−1.3
1 sessionsince 30 Sept	₹2,334.74	▼ −0.16%	▼ −0.88%	+0.72

Averages of the closeclose against each average

5-session average: ₹2,362.58close −1.3% from it
20-session average: ₹2,418.33close −3.6% from it
50-session average: ₹2,353.89close −0.97% from it
200-session average: ₹2,200.44close +5.9% from it

Range and volumetrue range over 14 sessions · high to low over 20 · volume against the 20-session average

Average true range, 14: ₹703.0% of the close
Average day's range, 20: ₹612.6% of the close
Volume against 20 sessions: 1.76×9.7 L vs 5.8 L average

Volatility and co-movement with Nifty 50annualised from daily log returns · counts share one denominator per cell

Realised volatility, 20: 30%≈ ±1.9% a session · moved more than that on 5 of 20
Realised volatility, 60: 26%≈ ±1.7% a session · moved more than that on 16 of 60
Realised volatility, 250: 27%≈ ±1.7% a session · moved more than that on 70 of 250
Beta to Nifty, 60: 0.83moved with Nifty on 34 of 60 sessions
Beta to Nifty, 250: 0.86moved with Nifty on 150 of 250 sessions

Up and down sessionscloses above and below the previous close

Last 20 sessions: 10 up · 10 downof 20
Last 60 sessions: 33 up · 27 downof 60
Last 250 sessions: 133 up · 116 downof 249
Best session, 250: ▲ +5.1%10 Mar
Worst session, 250: ▼ −5.6%22 May

9 bulletins on GLENMARK

latest 27 Mar 2026

Beats in the coverage

Often mentioned with

March 2026

27 Mar Indian stocks rise despite rupee plunge and FII sell-offIndian stocks rebounded with the Nifty up 1.72% to 23,306.45, driven by lower crude prices. However, the Indian Rupee hit record lows as foreign investors continued to withdraw funds, highlighting underlying economic challenges.Medium

February 2026

4 Feb Glenmark Pharma aims for zero debt by March 2026Glenmark Pharmaceuticals targets zero gross debt by March 2026, planning ₹800 cr in capital expenditures. The company aims to optimize its net working capital cycle, currently at 110 days, to enhance operational efficiency and financial strength.Medium 3 Feb Glenmark Pharma targets zero gross debt by March 2026Glenmark Pharmaceuticals plans to eliminate gross debt by March 2026, backed by a ₹800 crore capex plan. The company aims to optimize its net working capital cycle from about 110 days to 115 days, enhancing financial stability.Medium 1 Feb Glenmark Pharma faces GST search amid Q3 resultsGlenmark Pharma faces scrutiny from GST authorities with a search operation conducted from 27-31 Jan 2026. The company reported no adverse findings and stated no material impact on operations. Q3 results showed improvement, attracting trader attention.Medium 1 Feb Glenmark Pharma faces GST search amid Q3 resultsGlenmark Pharma shares will be in focus due to GST search operations at its offices from 27-31 Jan 2026. The company reported no material impact on its financials and released improved Q3 results after market hours on Friday.Medium

January 2026

31 Jan Glenmark Pharma Q3 profit rises 16%, SAIL exceeds estimatesGlenmark Pharma's Q3 profit rose 16%, while SAIL's profit more than doubled, exceeding estimates. These results could impact market sentiment ahead of the Union Budget.Medium 31 Jan Glenmark Pharma Q3 profit rises 16%, SAIL exceeds estimatesGlenmark Pharma's Q3 profit rose 16%, while SAIL's profit more than doubled, exceeding estimates. These results may influence market sentiment ahead of the upcoming Union Budget.Medium

November 2025

15 Nov Glenmark Pharma Q2 profit rises 72%, revenue up 76%High 15 Nov Q2 results: Ashoka Buildcon profit drops, Max Healthcare risesMedium

About Glenmark Pharmaceuticals Limited

exchange masters as of 18 Sept 2026 · classification by BSE

Company: Glenmark Pharmaceuticals Limited
Exchange: NSE · BSE 532296, group A
Listed on NSE: 7 Feb 2000
Classification: Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
Index: BSE 500
Face value: ₹1 a share
ISIN: INE935A01035
Sessions on record: 272
Price source: NSE UDiFF bhavcopy · end of day · delayed
Filings: NSE and BSE public disclosures · results, shareholding and corporate actions as filed
Computed: 1 Oct, 09:19 pm IST
Bulletins: 9 · written by the desk · not a recommendation

OI Charts is not a SEBI-registered investment adviser or research analyst. Prices, open interest, filings and the desk read are exchange data and arithmetic on it, not a basis for any investment decision.